Compare OFG & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFG | TNDM |
|---|---|---|
| Founded | 1964 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2013 |
| Metric | OFG | TNDM |
|---|---|---|
| Price | $41.46 | $22.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $45.75 | $24.00 |
| AVG Volume (30 Days) | 258.0K | ★ 1.4M |
| Earning Date | 01-22-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 6.55 | N/A |
| EPS | ★ 4.40 | N/A |
| Revenue | $624,004,000.00 | ★ $1,007,001,000.00 |
| Revenue This Year | N/A | $8.59 |
| Revenue Next Year | $1.02 | $10.19 |
| P/E Ratio | $9.39 | ★ N/A |
| Revenue Growth | N/A | ★ 17.87 |
| 52 Week Low | $33.15 | $9.98 |
| 52 Week High | $46.11 | $38.18 |
| Indicator | OFG | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 57.11 |
| Support Level | $40.91 | $21.35 |
| Resistance Level | $42.04 | $23.95 |
| Average True Range (ATR) | 0.71 | 0.91 |
| MACD | -0.10 | -0.13 |
| Stochastic Oscillator | 46.08 | 45.39 |
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.